- Home
- ANVS vs GDL Comparison
ANVS vs GDL Comparison
Compare ANVS & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | GDL |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 94.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | GDL |
|---|---|---|
| Price | $2.91 | $8.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 516.4K | 11.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $7.65 |
| 52 Week High | $5.50 | $8.13 |
Technical Indicators
Market Signals| Indicator | ANVS | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 35.55 | 46.73 |
| Support Level | $2.98 | $8.35 |
| Resistance Level | $3.30 | $8.49 |
| Average True Range (ATR) | 0.27 | 0.07 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 1.61 | 42.90 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.